Independent information resource
Guides, comparisons, and research summaries for approaching ibogaine and schizophrenia with caution, plain language, and attention to what remains uncertain.
Information offerings
These are informational resources for people affected by schizophrenia, their supporters, and anyone looking for careful context around ibogaine-related claims.
Structured explainers distinguish research interest from established care and keep the question of vulnerability to psychiatric destabilization in view. The wider ibogaine and schizophrenia overview sets the shared context for these guides.
Evidence summaries separate case reports, mechanistic discussion, and stronger forms of clinical evidence. The evidence summary pathway helps readers identify what a source can and cannot establish.
Comparisons organize questions about claims, uncertainty, screening language, and risk communication without presenting a decision as medical guidance. Our approach and information principles explain why careful limits matter.
Plain-language definitions and focused answers make recurring terms easier to assess, including psychosis, schizophrenia-spectrum conditions, and adverse-event language. Explore the clinical guidance FAQ collection for concise context.
Clinical context
Schizophrenia is a chronic mental disorder that can involve disruptions in thought, perception, emotion, and behavior; the National Institute of Mental Health overview of schizophrenia describes its symptoms and the importance of ongoing treatment planning.
Ibogaine is a psychoactive alkaloid associated with iboga, but curiosity about it does not amount to evidence of safety or suitability for schizophrenia-spectrum conditions. The reference description of ibogaine is useful background, while the clinical risks page keeps the practical safety questions in focus.
This resource also points readers to the independent ibogaine documentary project when broader public-facing context helps frame the subject; it does not replace individualized evaluation by qualified professionals.
Reading system
The aim is not to settle a personal medical decision. It is to make the available information easier to inspect without hiding its limits.
Short answers
No. Still Threshold 55 is an independent information resource. It does not provide diagnosis, treatment, prescribing, screening, or individualized medical advice.
It means describing what a source supports, naming uncertainty, and avoiding a stronger conclusion than the evidence can bear. For broad substance-use context, the National Institute on Drug Abuse discussion of drugs and the brain provides general background on how drugs can affect brain systems.
Schizophrenia-spectrum conditions introduce distinct questions about psychiatric history, symptom vulnerability, and risk communication. The clinical risk brief keeps those questions separate from broad claims about ibogaine.
The background on Still Threshold 55 explains the mission, values, and limits of this independent resource, including its emphasis on clinical humility and plain language.
Next reference point
The evidence summary is designed for readers who want a concise view of what can be said carefully about ibogaine and schizophrenia-spectrum conditions.